Vanda Pharmaceuticals Inc.

Hello and thank you for standing by. At this time, I would like to welcome you to the Q3 2024 Vander Pharmaceuticals, Inc. Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number 1 on your telephone keypad. If you would like to withdraw your question, press star 1 again. I would now like to turn the conference over to Kevin Moran, Vanda's Chief Financial Officer. Please go ahead, sir.

Thank you, Jericho. Good afternoon, and thank you for joining us to discuss Vanda Pharmaceutical's third quarter 2024 performance. Our third quarter 2024 results were released this afternoon and are available on the SEC's EDGAR system and on our website, www.vandapharma.com. In addition, we are providing live and archived versions of this conference call on our website. Joining me on today's call is Dr. Mahalis Polymeropoulos, our President, Chief Executive Officer and Chairman of the Board, and Tim Williams, our General Counsel. Following my introductory remarks, Mahalis will update you on our ongoing activities. I will then comment on our financial results before we open the lines for your questions. Before we proceed, I would like to remind everyone that various statements that we make on this call will be forward-looking statements within the meaning of federal securities laws. Our forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. These risks are described in the cautionary note regarding forward-looking statements, risk factors, and management's discussion and analysis of financial condition and results of operations sections of our most recent annual report on Form 10-K, as updated by our subsequent quarterly reports on Form 10-Q, current reports on Form 8-K, and other filings with the SEC, which are available on the SEC's EDGAR system and on our website. We encourage all investors to read these reports and our other filings. The information we provide on this call is provided only as of today. and we undertake no obligation to update or revise publicly any forward-looking statements we may make on this call on account of new information, future events, or otherwise, except as required by law. With that said, I would now like to turn the call over to our CEO, Dr. Mahalas Palimoropoulos.

Thank you very much, Kevin, and good afternoon, everyone. Thank you for joining us to discuss VANDIS third quarter 2024 results. During the last quarter, we have been focused on building and strengthening our commercial organization to support the new launches of FNAPT in bipolar I disorder and Punvori in multiple sclerosis. In Q3, we completed the first phase of our Salesforce build out to support the FNAPT launch with approximately 150 representatives marketing the product to psychiatry prescribers around the country. This launch has been supported by the FNAPT speakers program, creating awareness of the product among prescribers. The early indicators of commercial progress are encouraging and include more than 90% increase compared to Q3 of 2023 in new patient starts as captured by the IQVIA and BRX metric. This large increase is followed by observed increases in the NRX and TRX IQ metrics of new and total weekly prescriptions. We're observing a steady and continuous growth on adoption of the product with only a few months of operation of our enhanced national sales force. We have now initiated the second phase of sales force expansion that will bring the sales force to approximately 200 representatives by year end. We're excited with the commercial prospects of FNAPT, and we believe that significant growth can be accomplished in the near future. FNAPT is the flagship product of our psychiatry portfolio, which now also includes milsaperidone, an active metabolite of FNAPT, and FNAPT-LAI, long-acting injectable. A new drug application is planned for early 2025 for the indications of schizophrenia and bipolar I disorder for milsaperidone after a successful pre-NDA meeting with the FDA earlier this year. Additionally, we plan to initiate a Phase III program for milsaperidin in major depressive disorder this quarter. Success in this program is expected to significantly expand the potential of the franchise with the inclusion of the much more prevalent indication of depression. In addition, the pivotal long-term relapse prevention study with the once-monthly LAI FNAP is planned to start this quarter. We recently met with the FDA to discuss the potential NDA package for Fnapt-LAI, and we're in agreement that a successful completion of this upcoming study may be sufficient to support a new drug application for this product. I will now switch to Ponvori and our commercial efforts in multiple sclerosis, as well as our developing plans for indication expansion. Ponvori, a sphingosine 1-phosphate analog approved for the treatment of multiple sclerosis, was acquired last year from Janssen. In this last quarter, we built and launched our commercial sales team along with the Ponvori speakers program. The transition from Janssen was substantially completed in the third quarter after the transition of the marketing authorization was completed late in the second quarter. Our sales force, has received enthusiastic reception by many multiple sclerosis experts, some of whom were already familiar, while others are new to the product. Polivori is one of four products in this class and is differentiated by its receptor specificity and the quick onset and offset of action. In two recent publications, Clinician and Patient Preferences for sphingosine 1-phosphate analogs were examined in a discrete choice experiment design. Polvorio rose to the first choice position, both in the 200 U.S. neurologist study and the 400 multiple sclerosis patient study. The prescribers preferred ponesimod over siponimod, fingolimod, and ozanimod, primarily because of the fewer drug-drug interactions, while the multiple sclerosis patients chose ponesimod because of the shorter immune system recovery time in addition to the fewer drug-drug interactions. We look forward to increasing awareness of Ponvori among prescribers and patients over the coming quarters. Beyond multiple sclerosis, Ponvori has a potential utility in the treatment of other autoimmune disorders. In plaque psoriasis, Ponvori has shown significant efficacy in achieving PASI-75, the measurement of improvement of psoriasis score by week 16 in a large 326-patient study that included two doses of Ponvori and placebo. Both doses of Ponvori achieved the primary endpoint and showed highly significant results of p-value of less than 0.0001 for both doses tested. We expect to file an IND application for psoriasis with the FDA shortly. Successful completion of the program could result in a once-daily oral treatment for patients with psoriasis that may offer a convenient and effective option beyond the available injectable drugs. Separately, we have recently submitted an IND application to initiate a Ponvori program in ulcerative colitis. Again, here we believe that the successful completion of this program may bring a useful and differentiated option to patients with ulcerative colitis. On tradipitin, our neurokinin one receptor antagonist, we recently reported that the FDA denied approval for the treatment of symptoms of gastroparesis. We're disappointed with this decision as we believe that our application, the most expensive ever to be submitted to the FDA for this indication has already demonstrated substantial evidence of efficacy to warrant approval. The FDA's reasoning was mostly conclusory and not supported by the facts presented. This negative decision is especially disappointing for many patients with gastroparesis and especially for those that experience significant improvements in their condition where other treatments have failed for years. Dozens of patients are currently participating in the expanded access program, and many more have either applied or expressed interest to access tradipitant. We're committed to continue to pursue approval for this condition and support patients requesting expanded access. We believe that the best path forward would be for the FDA to convene the Scientific Advisory Committee to independently evaluate the evidence and offer their advice. In addition, we plan to initiate a clinical trial to study the effect of tradipitin in preventing vomiting in people treated with GLP-1 analogs, like semaglutide. Millions of patients are treated with GLP-1 analogs for diabetes and weight reduction, and a large portion of them experience nausea and vomiting, especially during the titration phase. We believe that tradipitin, because of its mechanism of action, has the potential to improve tolerability of these agents and permit more rapid titration, thereby improving the efficacy and safety profile of these useful agents. We have already shown in three adequate and well-controlled studies that tradipitin can be used to prevent vomiting induced by motion sickness. Traditionally, it has been shown to be effective at both doses tested during actual sea travel of the coastal waters of the United States. We plan to submit a new drug application for this indication by end of this year. While we highlight these programs, we continue our work to expand the indications for our approved products. Recently, we met with the FDA and agreed on a clinical program that could support the approval of hetlios in pediatric insomnia. Pediatric insomnia is a large unmet medical need with very few options and a very large burden to patients and their families. We believe that hetlios could have a significant public health impact in treating this very common pediatric condition. A clinical study in pediatric insomnia is underway. In our press release today, we briefly mentioned two other programs. The first with the CFTR activator VSJ110, which has shown encouraging results in dry eye disorder in an ongoing study. The second is a groundbreaking program in sarcoma tooth disease using antisensory nucleotide VCA894A, where this custom-developed drug is expected to be evaluated in a patient with this ultra-rare mutation later this year. In summary, we're excited with our FNAT loans and the revenue growth opportunities through all three of our commercial programs and look forward to providing updates on this as well as our promising pipeline in the future. With that, I'll turn now to Kevin to discuss our financial results. Kevin.

Thank you, Miles. I'll begin by summarizing our financial results for the first nine months of 2024 before turning to discuss the third quarter of 2024. Total revenues for the first nine months of 2024 were $145.6 million, a 1% decrease compared to $147.4 million for the same period in 2023. This slight decrease was primarily due to decreased Hetlios revenue due to the launch of generic versions of Hetlios, largely offset by the introduction of POMBORI revenue following our acquisition of the product in December 2023. Let me further break this down by product. FNAP net product sales were $67.6 million for the first nine months of 2024, a 1% decrease compared to $68.3 million in the same period in 2023. The decrease to net product sales relative to the first nine months of 2023 was attributable to a decrease in volume partially offset by an increase in price net of deductions. Hetlios net product sales were 56.6 million for the first nine months of 2024, a 28% decrease compared to 79.1 million in the same period in 2023. The decrease to net product sales relative to the first nine months of 2023 was attributable to a decrease in volume, partially offset by an increase in price net of deductions. The decrease relative to the first nine months of 2023 was a result of continued generic competition in the United States. Helios net product sales as reported for the first quarter of 2023 reflected higher unit sales as compared to recent prior periods. The higher unit sales during the first quarter of 2023 resulted in a significant increase of inventory stocking at specialty pharmacy customers at March 31st, 2023. During the remainder of 2023, although there was continued destocking at specialty pharmacy customers, inventory levels at December 31st, 2023 remained elevated relative to inventory levels prior to the entrance of generic competition and continue to remain elevated at March 31st, 2024, June 30th, 2024, and September 30th, 2024. Going forward, Hetlios net product sales may reflect lower unit sales as a result of reduction of the elevated inventory levels at specialty pharmacy customers or may be variable depending on when specialty pharmacy customers need to purchase again. Further, Hetlios net product sales will likely decline in future periods. potentially significantly, related to generic competition in the United States. Additionally, the company constrained Hetlios net product sales for the year ended December 31st, 2023 and the first nine months of 2024 to an amount not probable of significant revenue reversal. As a result, Hetlios net product sales could experience variability in future periods as the remaining uncertainties associated with variable consideration are resolved. Ponvori net product sales were 21.3 million for the first nine months of 2024. As a reminder, we completed the acquisition of the US and Canadian rights to Ponvori in December of 2023. As such, this represents the third full quarter of Ponvori revenue recognition at Vanda and a positive step in diversifying our product mix with innovative and value generating products. One additional item to note as we head into the fourth quarter of 2024 and soon thereafter 2025, the Medicare benefit redesign portion of the Inflation Reduction Act goes into effect as of January 1st, 2025. The implementation of the benefit redesign is expected to negatively impact gross to net for the Medicare payer segment of our products. This change is not specific to Vanda, but is an industry-wide change which will have varying impacts on pharmaceutical manufacturers. For the first nine months of 2024, Vanda reported a net loss of $14 million compared to net income of $4.9 million for the same period in 2023. The net loss for the first nine months of 2024 included an income tax benefit of $2.4 million as compared to an income tax provision of $3.1 million for the same period in 2023. Operating expenses for the first nine months of 2024 were $176 million compared to $154.2 million for the same period in 2023. The $21.7 million increase was primarily driven by higher SG&A expenses related to spending on Vanda's commercial products as a result of the commercial launches of Phenaptin Bipolar I Disorder and Ponvori and Multiple Sclerosis, and legal and other corporate activities, as well as higher intangible asset amortization expense due to the amortization recorded on the Ponvori intangible asset. During the first nine months of 2024, we commenced a host of activities as part of our commercial launches of Phenaptin Bipolar I Disorder and Ponvori and Multiple Sclerosis, including an expansion of our sales force, and the development of prescriber awareness and comprehensive marketing programs. SG&A expenses may increase in future periods as a result of the ongoing commercial launches of FNAPT in bipolar I disorder and PONVORI in multiple sclerosis, which were initiated in the third quarter of 2024. Vanda's cash, cash equivalents, and marketable securities, referred to as cash, as of September 30, 2024, was $376.3 million. representing a decrease of $12 million compared to December 31, 2023, and a decrease of $11.4 million compared to June 30, 2024. The cash balance of $376.3 million as of September 30, 2024 does not include a payment from Janssen for $8.1 million primarily related to second quarter 2024 PONVORI revenue receivables, which was received in the fourth quarter of 2024. If this payment had been received prior to September 30, 2024, the cash balance would have been 384.4 million, and the decrease to cash since December 31st, 2023 would have been 3.9 million, and the decrease to cash since June 30th, 2024 would have been 3.3 million. Turning now to our quarterly results. Total revenues for the third quarter of 2024 were 47.7 million, a 23% increase compared to 38.8 million for the third quarter of 2023, and a 6% decrease compared to $50.5 million in the second quarter of 2024. The increase as compared to the third quarter of 2023 was primarily due to the introduction of PONVORI revenue following our acquisition of the product in December 2023 and an increase in FNAP revenue. FNAP net product sales were $23.9 million for the third quarter of 2024, a 12% increase compared to $21.3 million in the third quarter of 2023. FNAP net product sales in the third quarter of 2024 increased by 3% as compared to 23.2 million in the second quarter of 2024. FNAP prescriptions in the third quarter of 2024, as reported by Equivia Exponent, increased by approximately 1% compared to the second quarter of 2024. Turning now to Hetlios. Hetlios net product sales were 17.9 million for the third quarter of 2024, a 2% increase compared to 17.5 million in the third quarter of 2023. Hetlio's net product sales in the third quarter decreased by 4% as compared to $18.7 million in the second quarter of 2024. The decrease in net product sales relative to the second quarter of 2024 was attributable to a decrease in volume partially offset by an increase in price net of deductions. And finally, turning to Pombori. Pombori net product sales were $5.9 million for the third quarter of 2024, a decrease of 32% compared to $8.6 million in the second quarter of 2024. The decrease in net product sales was attributable to a decrease in volume of units sold and a decrease in price net of deductions. The decrease in volume of units sold in the third quarter of 2024 was partially attributable to a temporary inventory destocking at the specialty distributors and pharmacies due to the final transition of distribution from Janssen to Vanda. The decrease in price net of deductions in the third quarter of 2024 was partially attributable to a true-up of prior period gross to net estimates. As a reminder, we completed the acquisition of the US and Canadian rights upon board in December of 2023. For the third quarter of 2024, Vanda recorded a net loss of 5.3 million compared to net income of 0.1 million for the third quarter of 2023. The net loss for the third quarter of 2024 included an income tax benefit of 0.9 million as compared to an income tax benefit of 0.3 million for the third quarter of 2023. Operating expenses in the third quarter of 2024 were $58.7 million compared to $44.8 million in the third quarter of 2023. The $13.8 million increase was primarily driven by higher SG&A expenses related to spending on Vanna's commercial products as a result of the commercial launches of Phenaptin Bipolar I Disorder and Pomphoria Multiple Sclerosis and legal and other corporate activities. Operating expenses in the third quarter of 2024 decreased by $2 million as compared to $60.6 million in the second quarter of 2024. This decrease is primarily driven by lower SG&A expenses related to legal and other corporate activities, partially offset by increased spending on Vanda's commercial products as a result of the commercial launches of Phenaptin Bipolar I Disorder and Fonvoria Multiple Sclerosis. During the first nine months of 2024, we commenced a host of activities as a result of the commercial launches of Phenaptin Bipolar I Disorder and Fonvoria Multiple Sclerosis, including an expansion of our sales force and the development of prescriber awareness and comprehensive marketing programs. SG&A expenses may increase in future periods as a result of the ongoing commercial launches of Phenaptin Bipolar I Disorder and Pombori and Multiple Sclerosis, which were initiated in the third quarter of 2024. With regards to the launches of Phenaptin Bipolar I Disorder and Pombori and Multiple Sclerosis, as I mentioned, those launches were initiated this quarter, the third quarter of 2024, and we expect our full commercial infrastructure to be in place by the end of this year, with the impact of these commercial efforts expected to begin to grow revenue later this year. We have already seen significant progress in our commercial activities. Several lead indicators suggest a strong initial market response, including new patient starts as reflected by new to brand prescriptions, or NBRX as reported by Equivia, increased by over 90% in the third quarter of 2024 as compared to the third quarter of 2023. Our FNAP sales force continues to expand. As of the end of the first quarter of 2024, our sales force numbered approximately 50 representatives. Currently, our sales force has grown to over 150 representatives, and we have now initiated a second phase of expansion, which will increase our sales force to approximately 200 representatives by the end of this year. In addition to our FNAP sales force, we've established a specialty sales force to market Pomvori to neurology prescribers around the country. The expansion has allowed us to significantly increase our reach and frequency with FNAP prescribers. The number of FNAP prescriber awareness programs completed in the third quarter of 2024 was nearly three times larger than the number of programs completed in the second quarter of 2024. Turning now to our financial guidance. Vanda is providing an update to its prior 2024 financial guidance. Vanda expects to achieve the following financial objectives in 2024. Total net product sales from FNAP, Tetleos, and Pombori of between $190 and $210 million. This compares to prior guidance of between $180 and $210 million. Year-end 2024 cash of between $370 million and $390 million. This compares to prior guidance of between $360 and $390 million. The revision upwards in our revenue guidance reflects the momentum we are seeing across our product portfolio, including the lead indicators referenced on our FNAP Bipolar 1 launch, progress on the Pompuri launch, which was initiated in the third quarter, and the continued durability of our Hetlios business. With that, I'll now turn the call back to Mahalis.

Thank you very much, Kevin. At this point, we will be happy to answer your questions.

Thank you. And we will now begin the question and answer session. If you have dialed in and would like to ask a question, please press star 1 on your telephone keypad to raise your hand and join the queue. If you would like to withdraw your question, simply press star one again. We're gonna pause for just a moment to compile the questions. Our first question comes from Charles Duncan from Canberra. The line's now open.

Hey, good afternoon, Mahalis and Kevin. Congrats on a nice quarter. need to see the new patient start increase for FNAPT and also pumping up the low end of revenue guidance. I wanted to ask you for a little bit more color on what your sales reps are seeing or hearing from these early days on the FNAPT relaunch, if you will, with the bipolar indication. I'm wondering if if you feel like your 150 reps are optimized and the 50 or so more are going to be necessary to drive, and if you are seeing a bump in TRX as well as NRX. Thanks.

Yeah, maybe I'll take the first part of the answer to this question. Thank you for joining us and thank you for the question. You're correct that we mentioned this very large increase on NB-RXs, which is a very lead indicator. These are people that have not been on FNAP for at least a look back of two years. And there we see this 90% increase. But we also see, following that, the increase on NRXs, which is both new starts and refills and TRXs with the total number of prescriptions. And the way it works is that the NBRX is the first indicator to see, followed by the NRX, and followed by the TRX. And when we look at them at a four-week or a three-month role in average, we see very substantial growth, and that is continuing. So to answer the question about whether we're optimized in size with the Salesforce, the answer is no, because the more reps we're putting in, the more growth we see. So we feel very good about that. We think that is a very good sign of the adoption of the program and identifying patients that benefit from it. But also, we're excited with the potentially very positive ROI in investments we can continue to make in this category. Now, this will not come as a surprise. because other products before us and currently are experiencing the same promotional sensitivity of antipsychotics in this space. So we feel very good that ours is responding, but we believe that continuous growth is to be had. not only with the current sales force that is just in place, but with further expansion as well. I don't know, Kevin, if you want to add.

The only other thing I would add to what Mahal has said there, Charles, is just in terms of what we're seeing from the sales force in terms of their interactions, is that we've seen a three- to four-fold increase in the number of interactions that our sales force has been able to have with potential FNAP prescribers. between the third quarter of this year and the first quarter of this year. So we've seen a fairly significant and dramatic increase in the number of interactions that we're having with prescribers, which obviously we believe is leading to the very significant growth that we're seeing in new patient starts, and hopefully will continue to transition or translate to growth in the NRX and TRX metrics, and ultimately revenue.

Okay, if I can sneak in another question on FNAP, then I had a quick question on the pipeline On FNAP, do you anticipate any impact of Bristol's launch of CoBenfi in terms of the broadening interest in prescribing FNAP?

Yeah. We are excited to see new programs and new mechanisms of action introduced for the treatment of mental disorders. Specifically, about Bristol's CUNBEFI product, the M4 muscarinic agonist, they are approved for schizophrenia only. And our focus now is primarily on bipolar I disorder. And therefore, we do not expect a direct negative effect. But rather, we believe investments that will be made in this space will renew the interest for many of the products in the class.

Okay. And then with regard to the pipeline, just really quickly, If considering the LAI for FNAP versus MILSA, what do you see as being most important in terms of being able to grow the franchise over time? And then given the pre-NDA meeting for MILSA periodone earlier this year, is there any data that you're expecting to enable the filing of that NDA in the first part of next year? or what is really the rate-limiting step on that MILSA, Peridone, and DA funding? Thanks.

Yeah, and I will start from that. I would say... Very little is in guarding the NDA filing. In fact, it is primarily guarded by the availability of the stability data, which will occur sometime in the first quarter. And based on this data, you'll have sufficient information for filing. In terms of clinical data, We are conducting a pharmacokinetic study examining a high dose of alloperidone versus a high dose of milsoperidone, and this study will be concluded shortly, and we don't expect it to impact the timing of the NDA filing. You asked a question about the relationship, I think, about the opportunity with the LAI and milsoperidone. I think always the most exciting thing with these drugs is the expansion of an indication. And certainly going from the smaller schizophrenia opportunity to larger bipolar I disorder to massive market for major depression, certainly that is a very significant opportunity expansion. But I will not underestimate the value of a well-tolerated and effective long-acting injectable like Phenapt, especially in the face of the very robust relapse prevention data that we have even with the oral Phenapt, and that is already on the U.S. label.

Excellent. Thanks for taking my questions. Congrats on a good call.

Thank you, Charles.

Our next question comes from . Your line is now open.

Thanks very much for taking my questions. Can you hear me? Yes, Ram. So firstly, I was wondering, maybe this is a question for Kevin. Can you provide us with a breakdown of the percentage of overall prescriptions for your three marketed products that is constituted by Medicare so that we can get a sense of what the differential impact across these three products of the Medicare benefit redesign might be.

Yep. Thanks for the question, Ram. So across the three products, maybe I'll just start with POMBORI, which is the one that we most recently acquired. What you tend to see across the class is that most of the payer mix there tends to lean towards the commercial side, with a much smaller portion being governmental. So we haven't kind of disclosed specifics in terms of actual percentages, but it's safe to assume that for POMVRI and for the rest of the class, that the majority of those prescriptions are going to be commercial, with a smaller portion being Medicare and Medicaid. On the FNAP side, Again, what you see in the class is that there's a stronger tilt towards the governmental payers there than there is in a product like Pomvori. And in the products that have a label beyond schizophrenia, you tend to see that to a little bit of a lesser extent. So for products that might have bipolar or depression, those have a stronger commercial element to them. than products that only have schizophrenia, which may be more concentrated in the governmental payer space. But it's safe to assume there that a significant portion of, potentially beyond half, are going to be coming from Medicare and Medicaid. And then finally on Hetlios, it's kind of a similar pattern on that side to what you would see in the FNAP atypical class, where you know, a good portion, more than half, is also coming from your governmental payers. So smaller portion on the Pombori side, larger portion on the Hetlios and FNAP side.

Okay. And then with respect to your planned timeline for the FNAP LAI Phase 3 program, can you just remind me when you expect that to start? What are the remaining gating items to initiation of enrollment in that program, and when you anticipate we might see top-line data?

Yeah, so I can tell you that we've recently met with the FDA and agreed on the design of the pivotal study, and the fact that it's successful, it can satisfy, it can be adequate for the efficacy portion of the FDA. This study is expected to be initiated shortly in the fourth quarter of 2024. It's a bit hard to anticipate the length of the study, but certainly these are studies that can expand beyond two years from start to finish, given the fact that their varied duration can span a period of about 52 weeks. That includes the stabilization and then treatment phase.

Okay. Can you also comment on the future potential applications of milsaperidone outside of the schizophrenia and bipolar disorder context? In particular, I was curious to know whether you think there might be applicability of milsaperidone in the mixed population of patients who exhibit symptoms of both depression and schizophrenia, much as has already been seen with Lumateparone.

Yeah. So two things there. First of all, I'll take the part of the mixed. And we know very well that this is a classification within the group of Bipolar I disorders that can be manic only, can have mixed features, or can have predominantly depressed features. Now, for FNAPT, the U.S. label is indeed for both manic and mixed features of bipolar I disorder. So this part of mixed, which means that the presence of manic and depressed symptoms being present, is already on the U.S. label for the indication. Now, what we're initiating shortly is the evaluation of milsaperidone as an adjunctive treatment to major depression. And as you know, a very large opportunity given the unmet medical need and what is known as a partial response to existing agents. And what we have seen from the history of application of atypical antipsychotics in the market it is that portion of patients that constitutes usually the largest portion of the commercial opportunity. And again, this pivotal study will be starting this quarter.

Great. And then just very quickly, with respect to the future potential indications and applications for PONVORI, can you give us some granularity regarding when you might look to initiate and investigative clinical development program in ulcerative colitis, or for that matter, any other indication that you think is particularly of interest?

Yes. So, you're correct in suspecting that there is a very large opportunity to use a sphingosine-1 phosphate as an autoimmune regulator for a number of disorders. For ulcerative colitis, we have just recently submitted an IND application and a protocol to the US FDA, and we expect to get their feedback and potentially initiate work there next year. For psoriasis, we are actually about to submit an IND, and certainly, as I mentioned in our We have a lot of excitement on the probability of technical success because a large 326-patient study has already been conducted with very persuasive efficacy on the primary endpoints of positive 75 at week 16. So there we think we're in good shape potentially with just one additional study to confirm the efficacy and safety of the product and develop then Punvori as a very attractive once-a-day oral medication for psoriasis. Remind you in our audience that there are drugs in psoriasis. Many of them are antibodies. against certain cytokines being TNF-alpha, IL-17, et cetera. And therefore, there is a need and an appetite for treating especially psoriasis flares with a convenient once-a-day oral medication that Ponvori can be.

Thank you very much, and congrats again on the quarter.

Thank you very much, Ron, for joining.

Our next question comes from Andrew Tsai from Jefferies. Their line is now open.

Hey, good afternoon. This is Matthew Barkas on for Andrew Tsai. I just had a couple questions. First off, congrats on the new-to-brand scripts for FNAP inflecting. I just want to know how you're balancing that with the launch at Pondvory, and were you able to resolve the destocking impact seen in Q3 completely, and Like how large of a Salesforce in comparison is your Pombori Salesforce compared to FinApp? And then when should we start to expect to see your marketing efforts there paying off?

I will let Kevin take on the more specific parts of the questions. But I will answer the balancing part between the FNAP and Punvori sales force. These are separate sales forces. The FNAP sales force is targeting specifically psychiatry prescribers, and they're focused on the bipolar indication of FNAP, where Punvori is a smaller specialty sales force targeting multiple sclerosis patients experts and centers around the country. Kevin?

A couple different pieces there, Matthew, that I'll hit. First, the question around the inventory destocking. What we saw there was that we completed the transition of the distribution responsibilities from Janssen to us in the middle of September, so fairly late in the quarter. As part of that, we saw a bit of inventory destocking at the specialty distributors and pharmacies You know, below levels that they've historically carried, and we've already seen that resolved in October. So that's not something that persisted beyond kind of the initial transition period where we were cutting over from one distributor to the other. The second question I think you asked there was how large of a sales force are we seeing on the Punvori side? And what we see there is that we've got a sales force in the neighborhood of about 30, which is in line with what we had as a specialty sales force previously on Hetlios when we had a dedicated specialty sales force on the Hetlios side. And then on the timing of the impact of these efforts, obviously we commenced the launch in the third quarter. As I mentioned in my portion of the script, we expect the infrastructure to be fully stood up this year. And we're hopeful to begin to see the impact of all those efforts on revenue later this year and as we head into next year.

Great. Thanks. And then also, you have quite a few early stage programs in development. Can you speak to your general strategy here? Like where does partnering or licensing out some of these programs make the most sense at all?

Yeah, certainly. So the way we view our strategy is to have a balanced risk development program with programs at different states of development, and that means risk, focus, and investment. And we believe we have a very good mix of early programs, late programs, and then lifecycle management of commercial products. Now, some of them, as they develop along, will remain to be seen whether they're a better opportunity to be fully developed and commercialized internally or with a partner or outlicensed. But at this time, we're happy where things are, and we had focused our business development activities in acquiring products like Bonvoy where they diversify the sources of revenue and, again, give us an opportunity of further indication expansion.

Great. Yeah, thank you so much, and congrats again on the quarter.

Thank you very much, Monkey.

There are no further questions at this time. I'll turn the call back over to the BANIS management.

Thank you very much for joining us this quarter. I will look forward to seeing you next time. Thank you.

This concludes today's call. Thank you for joining. You may now disconnect.